Cytokinetics, Incorporated (CYTK) Income Statement
CYTK 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCYTK revenue and net income
Where CYTK's revenue goes
2025Each bar shows an amount and its share of revenue. CYTK kept −891.6% of revenue as net income.
CYTK profit margins
CYTK growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +376.6% | −2.4% | +9.5% | +11.9% |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CYTK quarterly EPS vs estimates
Cytokinetics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 4, 2026 (estimate $-1.52).
CYTK income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88.0M | $18.5M | $7.5M | $94.6M | $70.4M | $55.8M | $26.9M | $31.5M | $13.4M | $106.4M |
| Cost of revenue | $10.1M | $339.4M | $330.1M | $240.8M | $159.9M | $97.0M | $86.1M | $89.1M | $90.3M | $59.9M |
| Gross profit | $77.9M | −$320.9M | −$322.6M | −$146.2M | −$89.5M | −$41.1M | −$59.3M | −$57.6M | −$76.9M | $46.5M |
| Research & development | $405.9M | $339.4M | $330.1M | $240.8M | $159.9M | $97.0M | $86.1M | $89.1M | $90.3M | $59.9M |
| Sales, general & admin | $284.3M | $215.3M | $173.6M | $178.0M | $96.8M | $52.8M | $39.6M | $31.3M | $36.5M | $27.8M |
| Total operating expenses | $690.2M | $215.3M | $173.6M | $178.0M | $96.8M | $52.8M | $39.6M | $31.3M | $36.5M | $27.8M |
| Operating income | −$612.3M | −$536.2M | −$496.2M | −$324.2M | −$186.3M | −$93.9M | −$98.9M | −$88.9M | −$113.4M | $18.7M |
| Interest income | $48.4M | $51.5M | $26.0M | $11.3M | $331,000 | $5.3M | $4.5M | $4.2M | $2.6M | $464,000 |
| Interest expense | $103.9M | $86.5M | $57.7M | $51.2M | $29.3M | $38.7M | $27.4M | $21.6M | $17.0M | $2.2M |
| Income before taxes | −$785.0M | −$589.5M | −$526.2M | −$389.0M | −$215.3M | −$127.3M | −$121.7M | −$106.3M | −$127.8M | $16.5M |
| Income taxes | — | — | $11.7M | $13.6M | $27.1M | $36.8M | $27.4M | $4.2M | $682,000 | −$741,000 |
| Net income | −$785.0M | −$589.5M | −$526.2M | −$389.0M | −$215.3M | −$127.3M | −$121.7M | −$106.3M | −$127.8M | $16.5M |
| EBITDA | −$774.8M | −$493.5M | −$456.7M | −$332.0M | −$183.7M | −$86.8M | −$93.0M | −$83.5M | −$108.9M | $19.4M |
| EPS (diluted) | −$5.52 | −$5.26 | −$5.45 | −$3.98 | −$2.83 | −$2.01 | −$2.12 | −$1.95 | −$2.57 | $0.30 |
| Gross margin | 88.5% | −1,737.2% | −4,284.1% | −154.6% | −127.1% | −73.7% | −220.5% | −183.0% | −575.5% | 43.7% |
| Operating margin | −695.4% | −2,902.7% | −6,589.7% | −342.8% | −264.5% | −168.3% | −368.0% | −282.3% | −848.3% | 17.6% |
| Net margin | −891.6% | −3,191.1% | −6,988.6% | −411.2% | −305.7% | −228.0% | −452.9% | −337.4% | −955.9% | 15.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.9M | $19.4M | $17.8M | $1.9M | $66.8M | $1.6M | $16.9M | $463,000 | $249,000 | $835,000 | $1.7M | $378,000 |
| Cost of revenue | $2.7M | $2.4M | $2.9M | $2.7M | $2.3M | $99.8M | $93.6M | $84.6M | $79.6M | $81.6M | $85.0M | $82.5M |
| Gross profit | $29.2M | $17.0M | $14.9M | −$743,000 | $64.5M | −$98.3M | −$76.7M | −$84.1M | −$79.3M | −$80.7M | −$83.3M | −$82.2M |
| Research & development | $97.8M | $95.5M | $101.5M | $99.2M | $112.6M | $99.8M | $93.6M | $84.6M | $79.6M | $81.6M | $85.0M | $82.5M |
| Sales, general & admin | $104.4M | $104.9M | $91.7M | $69.5M | $65.7M | $57.4M | $62.3M | $56.7M | $50.8M | $45.5M | $44.1M | $40.1M |
| Total operating expenses | $205.1M | $200.6M | $193.3M | $166.0M | $176.0M | $57.4M | $62.3M | $56.7M | $50.8M | $45.5M | $44.1M | $40.1M |
| Operating income | −$175.9M | −$183.6M | −$178.4M | −$166.8M | −$111.5M | −$155.6M | −$139.0M | −$140.8M | −$130.2M | −$126.2M | −$127.4M | −$122.3M |
| Interest income | $13.9M | $11.0M | $11.5M | $10.2M | $13.0M | $13.7M | $15.0M | $17.1M | $11.6M | $7.9M | $7.6M | $6.8M |
| Interest expense | $34.8M | $33.3M | $30.3M | $26.3M | $24.3M | $22.9M | $22.6M | $22.3M | $24.3M | $17.3M | $17.1M | $14.0M |
| Income before taxes | −$198.8M | −$206.0M | −$183.0M | −$306.2M | −$134.4M | −$161.4M | −$150.0M | −$160.5M | −$143.3M | −$135.6M | −$136.9M | −$129.4M |
| Income taxes | — | — | — | — | — | — | — | — | — | $2.3M | $1.8M | $6.9M |
| Net income | −$198.8M | −$206.0M | −$183.0M | −$306.2M | −$134.4M | −$161.4M | −$150.0M | −$160.5M | −$143.3M | −$135.6M | −$136.9M | −$129.4M |
| EBITDA | −$195.1M | −$169.3M | −$180.2M | −$277.2M | −$107.8M | −$136.1M | −$125.0M | −$135.8M | −$116.6M | −$116.0M | −$113.5M | −$113.6M |
| EPS (diluted) | −$1.50 | −$1.67 | −$1.50 | −$1.54 | −$1.12 | −$1.36 | −$1.26 | −$1.36 | −$1.31 | −$1.33 | −$1.38 | −$1.35 |
| Gross margin | 91.4% | 87.6% | 83.9% | −38.4% | 96.6% | −6,223.1% | −453.1% | −18,174.7% | −31,866.7% | −9,668.9% | −4,982.3% | −21,733.9% |
| Operating margin | −551.1% | −948.7% | −1,004.6% | −8,613.4% | −167.0% | −9,856.3% | −821.4% | −30,410.6% | −52,277.9% | −15,118.0% | −7,620.7% | −32,345.2% |
| Net margin | −622.8% | −1,064.5% | −1,030.9% | −15,815.0% | −201.2% | −10,220.1% | −886.3% | −34,674.9% | −57,557.4% | −16,244.7% | −8,187.6% | −34,238.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CYTK's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CYTK financial results
In fiscal year 2025 (ended December 31, 2025), Cytokinetics reported revenue of $88.0 million, up 376.6% from the year before. It had a net loss of $785.0 million, a net profit margin of −891.6%. Diluted earnings per share came to −$5.52. Over five years revenue grew at an average rate of 9.5% a year.
See the CYTK stock overview for the latest quote and news, or the CYTK chart for price history and technical indicators.
CYTK income statement FAQ
What is Cytokinetics's annual revenue?
Cytokinetics reported total revenue of $88.0 million for fiscal year 2025, which ended on December 31, 2025. That was up 376.6% from $18.5 million the previous year.
Is Cytokinetics profitable?
No. Cytokinetics reported a net loss of $785.0 million in fiscal 2025, a net profit margin of −891.6%; its operating margin was −695.4%.
What is Cytokinetics's gross margin?
Cytokinetics's gross margin was 88.5% in fiscal 2025: for every $100 of revenue, Cytokinetics kept $88 after the direct cost of its products and services.
How much does Cytokinetics spend on research and development?
Cytokinetics spent $405.9 million on research and development in fiscal 2025, 461.0% of revenue.
How fast is Cytokinetics growing?
Revenue grew 9.5% a year on average over the last five fiscal years, from $55.8 million to $88.0 million.
What are Cytokinetics's earnings per share?
Cytokinetics earned $-5.52 per diluted share in fiscal 2025, compared with $-5.26 a year earlier.
When will Cytokinetics report its next earnings?
Cytokinetics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does Cytokinetics's fiscal year end?
Cytokinetics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.